JPH027930B2 - - Google Patents
Info
- Publication number
- JPH027930B2 JPH027930B2 JP56165402A JP16540281A JPH027930B2 JP H027930 B2 JPH027930 B2 JP H027930B2 JP 56165402 A JP56165402 A JP 56165402A JP 16540281 A JP16540281 A JP 16540281A JP H027930 B2 JPH027930 B2 JP H027930B2
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- thrombin
- solution
- bonding
- calcium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010049003 Fibrinogen Proteins 0.000 claims description 29
- 102000008946 Fibrinogen Human genes 0.000 claims description 29
- 229940012952 fibrinogen Drugs 0.000 claims description 29
- 108090000190 Thrombin Proteins 0.000 claims description 14
- 229960004072 thrombin Drugs 0.000 claims description 14
- 208000010392 Bone Fractures Diseases 0.000 claims description 9
- 206010017076 Fracture Diseases 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 208000006735 Periostitis Diseases 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002031 ethanolic fraction Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56165402A JPS5867628A (ja) | 1981-10-15 | 1981-10-15 | 骨折治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56165402A JPS5867628A (ja) | 1981-10-15 | 1981-10-15 | 骨折治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5867628A JPS5867628A (ja) | 1983-04-22 |
| JPH027930B2 true JPH027930B2 (de) | 1990-02-21 |
Family
ID=15811720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56165402A Granted JPS5867628A (ja) | 1981-10-15 | 1981-10-15 | 骨折治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5867628A (de) |
-
1981
- 1981-10-15 JP JP56165402A patent/JPS5867628A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5867628A (ja) | 1983-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102362722B1 (ko) | 혈소판 풍부 혈장(prp) 또는 골수 농축물(bmc)을 단독으로 혹은 히알루론산과 결합하여 조제하기 위한 새로운 표준화 및 의료장비 | |
| JP4024302B2 (ja) | 微粒子および創傷治療におけるその用途 | |
| Tayapongsak et al. | Autologous fibrin adhesive in mandibular reconstruction with particulate cancellous bone and marrow | |
| ES2613378T3 (es) | Composiciones y métodos mínimamente invasivos para tratar la reparación incompleta de tejidos | |
| ES2333498B1 (es) | Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto. | |
| JPH0696039B2 (ja) | 組織接着剤並びにその製造方法 | |
| JP5801789B2 (ja) | トロンビンを含まない生物学的接着剤及びその医薬としての使用 | |
| DK150815B (da) | Fremgangsmaade til fremstilling af et vaevsklaebestof paa basis af humane eller animalske proteiner fra blod | |
| EP0172710A2 (de) | Blutstillendes Mittel | |
| JP2021523097A (ja) | 止血組成物を調製する方法 | |
| KR100971271B1 (ko) | 헤파린이 결합된 피브린젤, 그 제조방법 및 키트 | |
| ES2216323T3 (es) | Medicina para promover la cicatrizacion y que contiene trombocitos. | |
| ES2539515T3 (es) | Dispositivo de coágulo derivado de sangre entera para el tratamiento de defectos óseos | |
| WO2018048199A1 (ko) | 가교화 히알루론산 유도체 매트릭스가 포함된 지혈 조성물 | |
| JPH0199565A (ja) | フィブリン糊調製用キット | |
| JP2715104B2 (ja) | トロンビン乾燥製剤 | |
| CN113827778B (zh) | 一种注射式骨修复剂及其应用 | |
| CN113797384B (zh) | 一种注射式骨修复剂的制备方法 | |
| WO2019213285A1 (en) | Systems and methods for local modulation of wnt signaling | |
| JPS62190127A (ja) | 傷の治癒を促進するための合成多硫酸化オリゴ糖含有組成物 | |
| JPH027930B2 (de) | ||
| JP6877360B2 (ja) | 止血組成物 | |
| KR101110317B1 (ko) | 조직재생을 위한 티모신 베타-4 유래 Ａｃ-ＳＤＫＰ 펩타이드의 스마트 방출지지체 | |
| JPH02218618A (ja) | トロンビン粉末製剤 | |
| JP2526073B2 (ja) | 異常破水治療剤 |